以肠道菌群为靶点治疗原发性胆汁性胆管炎的临床应用

摘要：原发性胆汁性胆管炎（PBC）是一种以胆管上皮细胞为特征性靶标的进行性胆汁淤积性肝病。“疾病肠治”是近年的研究热点。未来或可通过益生菌改善肠道菌群丰度及分布，重塑肠道微环境，进而干预PBC疾病进展。本文从肠道菌群角度及益生菌的临床应用方面进行综述，为PBC寻找新的治疗策略提供思路。

关键词：肝硬化， 胆汁性； 胃肠道微生物组； 治疗学

基金项目：内蒙古自治区卫生健康科技计划项目（202201282）;  内蒙古自治区自然科学基金项目（2022LHMS08019）

Treatment of primary biliary cholangitis by targeting intestinal flora

MA Minghan， LIU Yanqi. （Department of Gastroenterology， The Affiliated Hospital of Inner Mongolia Medical University， Huhehot 010050， China）

Corresponding author：LIU Yanqi， 109307436@qq.com （ORCID：0000-0002-4735-6712）

Abstract：Primary biliary cholangitis （PBC） is a progressive cholestatic liver disease targeting biliary epithelial cells， and the concept of “treating diseases by intervening with the gut” has become a research hotspot in recent years. In the future， probiotics may be used to improve the abundance and distribution of intestinal flora， reshape the intestinal microenvironment， and intervene against the progression of PBC. This article reviews the gut microbiota and the clinical application of probiotics， so as to provide ideas for finding new treatment strategies for PBC.

Key words：Liver Cirrhosis， Biliary; Gastrointestinal Microbiome; Therapeutics

Research funding：Health  Science and Technology Project of Inner Mongolia（202201282）; Natural Science Foundation of the Inner Mongolia（2022LHMS08019）

原发性胆汁性胆管炎（PBC）是一种以肝内胆管上皮细胞（biliary epithelia cell，BEC）为特征性靶标的具有器官特异性的自身免疫相关肝病。（剩余11622字）